L. Ward, E. Imel, M. Whyte, C. Munns, A. Portale, W. Högler, J. Simmons, R. Padidela, N. Namba, H. Cheong, O. Nilsson, M. Mao, A. Skrinar, Chao‐Yin Chen, J. Martín, F. Glorieux
{"title":"对于年龄较小(1-4岁)和年龄较大(5-12岁)的x连锁低磷血症儿童,与继续常规治疗相比,Burosumab的临床结果改善更大","authors":"L. Ward, E. Imel, M. Whyte, C. Munns, A. Portale, W. Högler, J. Simmons, R. Padidela, N. Namba, H. Cheong, O. Nilsson, M. Mao, A. Skrinar, Chao‐Yin Chen, J. Martín, F. Glorieux","doi":"10.1530/boneabs.7.oc14","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9160,"journal":{"name":"Bone Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia\",\"authors\":\"L. Ward, E. Imel, M. Whyte, C. Munns, A. Portale, W. Högler, J. Simmons, R. Padidela, N. Namba, H. Cheong, O. Nilsson, M. Mao, A. Skrinar, Chao‐Yin Chen, J. Martín, F. Glorieux\",\"doi\":\"10.1530/boneabs.7.oc14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9160,\"journal\":{\"name\":\"Bone Abstracts\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bone Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1530/boneabs.7.oc14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/boneabs.7.oc14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia